Citigroup Maintains Buy on Zymeworks, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a Buy rating on Zymeworks (NASDAQ:ZYME) and raises the price target from $17 to $18.
May 18, 2023 | 10:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup maintains a Buy rating on Zymeworks and raises the price target from $17 to $18.
Citigroup's decision to maintain a Buy rating on Zymeworks and raise the price target from $17 to $18 indicates a positive outlook for the company's stock. This news is likely to have a positive impact on ZYME's stock price in the short term as it reflects the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100